Lead with METTL3 STORM’s lead candidate STC-15 is a first-in-class METTL3 inhibitor in Phase I for cancer, presenting a clear entry point for collaboration in oncology partnerships, clinical development support, and potential co-development discussions with pharma companies seeking RNA modification targets.

Clinical Momentum Recent IND filing and ongoing Phase I dose-escalation data with sarcoma focus position STORM as a clinically compelling partner for investors and CROs, offering opportunities for sponsored research deals, investigator-initiated trials, and strategic financing discussions tied to platform-enabled assets.

Strategic Partnerships STORM leverages in-house R&D complemented by high-quality CRO engagement (e.g., Evotec), signaling openness to expanded outsourcing, co-development agreements, and milestone-based collaborations to accelerate discovery and reduce internal burn rate.

Global Presence Headquartered in Cambridge, UK with activity at the Babraham Research Campus and visible activity at major conferences (ASCO), STORM offers access to European and US oncology networks, potential clinic-to-company partnerships, and opportunities for joint events to raise visibility.

Financial and Growth Signals With a Series C of $56M in 2026 and a broad, venture-backed pipeline targeting oncology, inflammation, viral infections, and CNS diseases, there is potential for partnerships around multi-asset licensing, platform-wide collaborations, and fundable co-ops to scale preclinical to clinic.